Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics, Positive Bio Partner on MDx Testing in India

NEW YORK (GenomeWeb) – Indian genomics testing firm Positive Bioscience announced today a partnership with Myriad Genetics to offer molecular diagnostic testing in that country. 

As part of the deal, Myriad will make available its tests covering nine cancers. They include BRACAnalysis to identify the risk of breast and ovarian cancer; Colaris to identify hereditary colorectal cancer; and myRisk, which assesses the risk of developing breast, prostate, endometrial, melanoma, pancreatic, colorectal, gastric, and ovarian cancer. 

Myriad also will offer its EndoPredict prognostic test for breast cancer, and Prolaris prognostic test for prostate cancer. All testing will be conducted at Myriad's laboratories in the US and Germany. 

"With our wide reach, thousands of Indians will instantly have access to world-class testing," Positive Bioscience CEO Samarth Jain said in a statement. "These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives." 

Financial and other terms of the deal were not disclosed. 

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.